Corticosteroids as adjunctive therapy in the treatment of influenza
- PMID: 26950335
- DOI: 10.1002/14651858.CD010406.pub2
Corticosteroids as adjunctive therapy in the treatment of influenza
Update in
-
Corticosteroids as adjunctive therapy in the treatment of influenza.Cochrane Database Syst Rev. 2019 Feb 24;2(2):CD010406. doi: 10.1002/14651858.CD010406.pub3. Cochrane Database Syst Rev. 2019. PMID: 30798570 Free PMC article.
Abstract
Background: Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefit or harm.
Objectives: To systematically assess the effectiveness and potential adverse effects of corticosteroids as adjunctive therapy in the treatment of influenza, taking into account differences in timing and doses of corticosteroids.
Search methods: We searched CENTRAL (2015, Issue 5), MEDLINE (1946 to June week 1, 2015), EMBASE (1974 to June 2015), CINAHL (1981 to June 2015), LILACS (1982 to June 2015), Web of Science (1985 to June 2015), abstracts from the last three years of major infectious disease and microbiology conferences, and references of included articles.
Selection criteria: We included randomised controlled trials (RCTs), quasi-RCTs and observational studies that compared corticosteroid treatment with no corticosteroid treatment for influenza or influenza-like illness. We did not restrict studies by language of publication, influenza subtypes, clinical setting or age of participants. We selected eligible studies in two stages: sequential examination of title and abstract, followed by full text.
Data collection and analysis: Two pairs of review authors independently extracted data and assessed risk of bias. We pooled estimates of effect using random-effects meta-analysis models, where appropriate. We assessed heterogeneity using the I(2) statistic and assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
Main results: We identified 19 eligible studies (3459 individuals), all observational; 13 studies (1917 individuals) were suitable for inclusion in the meta-analysis of mortality. Of these, 12 studied patients infected with 2009 influenza A H1N1 virus (H1N1pdm09). Risk of bias was greatest in the 'comparability domain' of the Newcastle-Ottawa scale, consistent with potential confounding by indication. Data specific to mortality were of very low quality. Reported doses of corticosteroids used were high and indications for their use were not well reported. On meta-analysis, corticosteroid therapy was associated with increased mortality (odds ratio (OR) 3.06, 95% confidence interval (CI) 1.58 to 5.92). Pooled subgroup analysis of adjusted estimates of mortality from four studies found a similar association (OR 2.82, 95% CI 1.61 to 4.92). Three studies reported greater odds of hospital-acquired infection related to corticosteroid therapy; all were unadjusted estimates and we graded the data as very low quality.
Authors' conclusions: We did not identify any completed RCTs of adjunctive corticosteroid therapy for treating influenza. The available evidence from observational studies is of very low quality with confounding by indication a major potential concern. Although we found that adjunctive corticosteroid therapy was associated with increased mortality, this result should be interpreted with caution. In the context of clinical trials of adjunctive corticosteroid therapy in sepsis and pneumonia that report improved outcomes, including decreased mortality, more high-quality research is needed (both RCTs and observational studies). Currently, we do not have sufficient evidence in this review to determine the effectiveness of corticosteroids for patients with influenza.
Similar articles
-
Corticosteroids as adjunctive therapy in the treatment of influenza.Cochrane Database Syst Rev. 2019 Feb 24;2(2):CD010406. doi: 10.1002/14651858.CD010406.pub3. Cochrane Database Syst Rev. 2019. PMID: 30798570 Free PMC article.
-
Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis.Crit Care Med. 2020 Feb;48(2):e98-e106. doi: 10.1097/CCM.0000000000004093. Crit Care Med. 2020. PMID: 31939808
-
Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis.J Infect Dis. 2015 Jul 15;212(2):183-94. doi: 10.1093/infdis/jiu645. Epub 2014 Nov 18. J Infect Dis. 2015. PMID: 25406333 Review.
-
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.Cochrane Database Syst Rev. 2015 Apr 2;2015(4):CD006150. doi: 10.1002/14651858.CD006150.pub2. Cochrane Database Syst Rev. 2015. PMID: 25835432 Free PMC article. Review.
-
The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness.Crit Care. 2016 Mar 30;20:75. doi: 10.1186/s13054-016-1230-8. Crit Care. 2016. PMID: 27036638 Free PMC article.
Cited by
-
Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome.Biomedicines. 2024 Mar 29;12(4):761. doi: 10.3390/biomedicines12040761. Biomedicines. 2024. PMID: 38672119 Free PMC article. Review.
-
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].Med Intensiva. 2021 Mar;45(2):104-121. doi: 10.1016/j.medin.2020.06.017. Epub 2020 Jul 11. Med Intensiva. 2021. PMID: 38620757 Free PMC article. Spanish.
-
Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review.Cureus. 2023 Oct 12;15(10):e46893. doi: 10.7759/cureus.46893. eCollection 2023 Oct. Cureus. 2023. PMID: 37954793 Free PMC article. Review.
-
An IL-17-EGFR-TRAF4 axis contributes to the alleviation of lung inflammation in severe influenza.Commun Biol. 2023 Jun 3;6(1):600. doi: 10.1038/s42003-023-04982-0. Commun Biol. 2023. PMID: 37270623 Free PMC article.
-
Severe community-acquired pneumonia.Eur Respir Rev. 2022 Dec 14;31(166):220123. doi: 10.1183/16000617.0123-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36517046 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical